Clavis Pharma ASA has applied for listing on the Oslo Stock Exchange and plans to go public this summer. The company, which is backed by NeoMed, plans to conduct an IPO in the order of NOK 200m. The present largest shareholders intend to participate with further investments in the IPO.
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater